Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells

Molecular and Cellular Biology

Volumn 22, Issue 23, 2002, Pages 8184-8198

  Law, Brian K ^a   Chytil, Anna ^a   Dumont, Nancy ^a   Hamilton, Elizabeth G ^a   Waltner Law, Mary E ^a   Aakre, Mary E ^a   Covington, Cassondra ^a   Moses, Harold L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; DRUG RECEPTOR; FK 506 BINDING PROTEIN; MYC PROTEIN; PROTEIN P107; PROTEIN P130; PROTEIN P21; PROTEIN P27; RAPAMYCIN; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME REPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA-BINDING PROTEINS; E2F4 TRANSCRIPTION FACTOR; ENZYME INHIBITORS; EPITHELIAL CELLS; GENES, REPORTER; GROWTH INHIBITORS; HUMANS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 0036888908     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.22.23.8184-8198.2002     Document Type: Article

References (91)

1. Abe, M., J. G. Harpel, C. N. Metz, I. Nunes, D. J. Loskutoff, and D. B. Rifkin. 1994. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216:276-284.
2. Adjei, A. A. 2001. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93:1062-1074.
3. Afshari, C. A., M. A. Nichols, Y. Xiong, and M. Mudryj. 1996. A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts. Cell Growth Differ. 7:979-988.
4. Aghdasi, B., K. Ye, A. Resnick, A. Huang, H. C. Ha, X. Guo, T. M. Dawson, V. L. Dawson, and S. H. Snyder. 2001. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc. Natl. Acad. Sci. USA 98:2425-2430.
5. Alexandrow, M. G., M. Kawabata, M. Aakre, and H. L. Moses. 1995. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA 92:3239-3243.
6. Bahram, F., N. von der Lehr, C. Cetinkaya, and L. G. Larsson. 2000. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95:2104-2110.
7. Barrack, E. R. 1997. TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity. Prostate 31:61-70.
8. Bhatia, K., K. Huppi, G. Spangler, D. Siwarski, R. Iyer, and I. Magrath. 1993. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet. 5:56-61.
9. Bhowmick, N. A., R. Zent, M. Ghiassi, M. McDonnell, and H. L. Moses. 2001. Integrin beta 1 signaling is necessary for transforming growth factorbeta activation of p38MAPK and epithelial plasticity. J. Biol. Chem. 276:46707-46713.
10. Bookstein, R., J. Y. Shew, P. L. Chen, P. Scully, and W. H. Lee. 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715.
11. Bottinger, E. P., J. L. Jakubczak, D. C. Haines, K. Bagnall, and L. M. Wakefield. 1997. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57:5564-5570.
12. Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. Lane, and S. L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-758.
13. Brunn, G. J., C. C. Hudson, A. Sekulic, J. M. Williams, H. Hosoi, P. J. Houghton, J. C. Lawrence, Jr., and R. T. Abraham. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101.
14. Chen, C. R., Y. Kang, and J. Massague. 2001. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc. Natl. Acad. Sci. USA 98:992-999.
15. Chen, Y. G., F. Liu, and J. Massague. 1997. Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J. 16:3866-3876.
16. Cipriano, S. C., and Y. Q. Chen. 1998. Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. Oncogene 17:1549-1556.
17. Claassen, G. F., and S. R. Hann. 2000. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc. Natl. Acad. Sci. USA 97:9498-9503.
18. Coats, S., P. Whyte, M. L. Fero, S. Lacy, G. Chung, E. Randel, E. Firpo, and J. M. Roberts. 1999. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells. Curr. Biol. 9:163-173.
19. Collado, M., R. H. Medema, I. Garcia-Cao, M. L. Dubuisson, M. Barradas, J. Glassford, C. Rivas, B. M. Burgering, M. Serrano, and E. W. Lam. 2000. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J. Biol. Chem. 275:21960-21968.
20. Dennler, S., S. Itoh, D. Vivien, P. ten Dijke, S. Huet, and J. M. Gauthier. 1998. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:3091-3100.
21. Dudkin, L., M. B. Dilling, P. J. Cheshire, F. C. Harwood, M. Hollingshead, S. G. Arbuck, R. Travis, E. A. Sausville, and P. J. Houghton. 2001. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7:1758-1764.
22. Dumont, N., M. D. O'Connor-McCourt, and A. Philip. 1995. Transforming growth factor-beta receptors on human endometrial cells: Identification of the type I, II, and III receptors and glycosyl-phosphatidylinositol anchored TGF-beta binding proteins. Mol. Cell. Endocrinol. 111:57-66.
23. Feng, L. X., N. Ravindranath, and M. Dym. 2000. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J. Biol. Chem. 275:25572-25576.
24. Feng, X. H., Y. Y. Liang, M. Liang, W. Zhai, and X. Lin. 2002. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol. Cell 9:133-143.
25. Geoerger, B., K. Kerr, C. B. Tang, K. M. Fung, B. Powell, L. N. Sutton, P. C. Phillips, and A. J. Janss. 2001. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61:1527-1532.
26. Goustin, A. S., E. B. Leof, G. D. Shipley, and H. L. Moses. 1986. Growth factors and cancer. Cancer Res. 46:1015-1029.
27. Grewe, M., F. Gansauge, R. M. Schmid, G. Adler, and T. Seufferlein. 1999. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 59:3581-3587.
28. Guadagno, T. M., and J. W. Newport. 1996. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 84:73-82.
29. Hashermolhosseini, S., Y. Nagamine, S. J. Morley, S. Desrivieres, L. Mercep, and S. Ferrari. 1998. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. 273:14424-14429.
30. Heitman, J., N. R. Movva, and M. N. Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909.
31. Hentges, K. E., B. Sirry, A. C. Gingeras, D. Sarbassov, N. Sonenberg, D. Sabatini, and A. S. Peterson. 2001. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc. Natl. Acad. Sci. USA 98:13796-13801.
32. Hiebert, S. W., M. Lipp, and J. R. Nevins. 1989. E1A-dependent transactivation of the human MYC promoter is mediated by the E2F factor. Proc. Natl. Acad. Sci. USA 86:3594-3598.
33. Hoang, A. T., B. Lutterbach, B. C. Lewis, T. Yano, T.-Y. Chou, J. F. Barrett, M. Raffeld, S. R. Hann, and C. V. Dang. 1995. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol. Cell. Biol. 15:4031-4042.
34. Hosoi, H., M. B. Dilling, L. N. Liu, M. K. Danks, T. Shikata, A. Sekulic, R. T. Abraham, J. C. Lawrence, Jr., and P. J. Houghton. 1998. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol. 54:815-824.
35. Howe, P. H., S. F. Dobrowolski, K. B. Reddy, and D. W. Stacey. 1993. Release from G1 growth arrest by transforming growth factor beta 1 requires cellular ras activity. J. Biol. Chem. 268:21448-21452.
36. Jo, H., R. Zhang, H. Zhang, T. A. McKinsey, J. Shao, R. D. Beauchamp, D. W. Ballard, and P. Liang. 2000. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene 19:841-849.
37. Ju, W. D., T. J. Velu, W. C. Vass, A. G. Papageorge, and D. R. Lowy. 1991. Tumorigenic transformation of NIH 3T3 cells by the autocrine synthesis of transforming growth factor alpha. New Biol. 3:380-388.
38. Kerr, D. I., J. A. Plumb, R. I. Freshney, M. Z. Khan, and D. A. Spandidos. 1991. The effect of H-ras oncogene transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs. Anticancer Res. 11:1349-1352.
39. Keski-Oja, J., E. B. Leof, R. M. Lyons, R. J. Coffey, Jr., and H. L. Moses. 1987. Transforming growth factors and control of neoplastic cell growth. J. Cell. Biochem. 33:95-107.
40. Kitamura, T., M. Onishi, S. Kinoshita, A. Shibuya, A. Miyajima, and G. P. Nolan. 1995. Efficient screening of retroviral cDNA expression libraries. Proc. Natl. Acad. Sci. USA 92:9146-9150.
41. Ko, T. C., W. Yu, T. Sakai, H. Sheng, J. Shao, R. D. Beauchamp, and E. A. Thompson. 1998. TGF-beta1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene 16:3445-3454.
42. Law, B. K., P. Norgaard, L. Gnudi, B. B. Kahn, H. S. Poulson, and H. L. Moses. 1999. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J. Biol. Chem. 274:4743-4748.
43. Law, B. K., M. E. Waltner-Law, A. J. Entingh, A. Chytil, M. E. Aakre, P. Norgaard, and H. L. Moses. 2000. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-Myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J. Biol. Chem. 275:38261-38267.
44. Lenferink, A. E., D. Busse, W. M. Flanagan, F. M. Yakes, and C. L. Arteaga. 2001. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res. 61:6583-6591.
45. Leone, G., J. DeGregori, R. Sears, L. Jakoi, and J. R. Nevins. 1997. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387:422-426. (Erratum, 387:932.)
46. Li, J. M., P. P. Hu, X. Shen, Y. Yu, and X. F. Wang. 1997. E2F4-RB and E2F4-p107 complexes suppress gene expression by transforming growth factor beta through E2F binding sites. Proc. Natl. Acad. Sci. USA 94:4948-4953.
47. Liao, D. J., and R. B. Dickson. 2000. c-Myc in breast cancer. Endocr. Relat. Cancer 7:143-164.
48. Liu, X., Y. Sun, S. N. Constantinescu, E. Karam, R. A. Weinberg, and H. F. Lodish. 1997. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc. Natl. Acad. Sci. USA 94:10669-10674.
49. Liu, X., Y. Sun, M. Ehrlich, T. Lu, Y. Kloog, R. A. Weinberg, H. F. Lodish, and Y. I. Henis. 2000. Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 19:5926-5935.
50. Lorenz, M. C., and J. Heitman. 1995. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J. Biol. Chem. 270:27531-27537.
51. Meraldi, P., J. Lukas, A. M. Fry, J. Bartek, and E. A. Nigg. 1999. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat. Cell Biol. 1:88-93.
52. Moberg, K. H., T. J. Logan, W. A. Tyndall, and D. J. Hall. 1992. Three distinct elements within the murine c-myc promoter are required for transcription. Oncogene 7:411-421.
53. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
54. Moses, H. L., R. J. Coffey, Jr., E. B. Leof, R. M. Lyons, and J. Keski-Oja. 1987. Transforming growth factor beta regulation of cell proliferation. J. Cell. Physiol. Suppl. 5(Suppl.):1-7.
55. Muise-Helmericks, R. C., H. L. Grimes, A. Bellacosa, S. E. Malstrom, P. N. Tsichlis, and N. Rosen. 1998. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273:29864-29872.
56. Munger, K., J. A. Pietenpol, M. R. Pittelkow, J. T. Holt, and H. L. Moses. 1992. Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ. 3:291-298.
57. Nagahara, H., S. A. Ezhevsky, A. M. Vocero-Akbani, P. Kaldis, M. J. Solomon, and S. F. Dowdy. 1999. Transforming growth factor beta targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc. Natl. Acad. Sci. USA 96:14961-14966.
58. Nakayama, K., N. Ishida, M. Shirane, A. Inomata, T. Inoue, N. Shishido, I. Horii, and D. Y. Loh. 1996. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.
59. Nesbit, C. E., J. M. Tersak, and E. V. Prochownik. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18:3004-3016.
60. Neshat, M. S., I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98:10314-10319.
61. Nourse, J., E. Firpo, W. M. Flanagan, S. Coats, K. Polyak, M. H. Lee, J. Massague, G. R. Crabtree, and J. M. Roberts. 1994. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573.
62. Okadome, T., E. Oeda, M. Saitoh, H. Ichijo, H. L. Moses, K. Miyazono, and M. Kawabata. 1996. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. J. Biol. Chem. 271:21687-21690.
63. Park, B. J., J. I. Park, D. S. Byun, J. H. Park, and S. G. Chi. 2000. Mitogenic conversion of transforming growth factor-betal effect by oncogenic Ha-Rasinduced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res. 60:3031-3038.
64. Pasche, B. 2001. Role of transforming growth factor beta in cancer. J. Cell. Physiol. 186:153-168.
65. Pasche, B., P. Kolachana, K. Nafa, J. Satagopan, Y. G. Chen, R. S. Lo, D. Brener, D. Yang, L. Kirstein, C. Oddoux, H. Ostrer, P. Vineis, L. Varesco, S. Jhanwar, L. Luzzatto, J. Massague, and K. Offit. 1999. TbetaR-1(6A) is a candidate tumor susceptibility allele. Cancer Res. 59:5678-5682.
66. Pierce, D. F., Jr., A. E. Gorska, A. Chytil, K. S. Meise, D. L. Page, R. J. Coffey, Jr., and H. L. Moses. 1995. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc. Natl. Acad. Sci. USA 92:4254-4258.
67. Pietenpol, J. A., K. Munger, P. M. Howley, R. W. Stein, and H. L. Moses. 1991. Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proc. Natl. Acad. Sci. USA 88:10227-10231.
68. Pietenpol, J. A., R. W. Stein, E. Moran, P. Yaciuk, R. Schlegel, R. M. Lyons, M. R. Pittelkow, K. Munger, P. M. Howley, and H. L. Moses. 1990. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61:777-785.
69. Pulverer, B. J., C. Fisher, K. Vousden, T. Littlewood, G. Evan, and J. R. Woodgett. 1994. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9:59-70.
70. Reinhard, C., A. Fernandez, N. J. Lamb, and G. Thomas. 1994. Nuclear localization of p85s6k: Functional requirement for entry into S phase. EMBO J. 13:1557-1565.
71. Sabatini, D. M., H. Erdjument-Bromage, M. Lui, P. Tempst, and S. H. Snyder. 1994. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43.
72. Salghetti, S. E., S. Y. Kim, and W. P. Tansey. 1999. Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc. EMBO J. 18:717-726.
73. Schwarz, J. K., C. H. Bassing, I. Kovesdi, M. B. Datto, M. Blazing, S. George, X. F. Wang, and J. R. Nevins. 1995. Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. Proc. Natl. Acad. Sci. USA 92:483-487.
74. Seoane, J., C. Pouponnot, P. Staller, M. Schader, M. Eilers, and J. Massague. 2001, TGFbeta influences Mye, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 3:400-408.
75. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
76. Staller, P., K. Peukert, A. Kiermaier, J. Seoane, J. Lukas, H. Karsunky, T. Moroy, J. Bartek, J. Massague, F. Hanel, and M. Eilers. 2001. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3:392-399.
77. Stockwell, B. R., and S. L. Schreiber. 1998. TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem. Biol. 5:385-395.
78. Tang, B., E. P. Bottinger, S. B. Jakowlew, K. M. Bagnall, J. Mariano, M. R. Anver, J. J. Letterio, and L. M. Wakefield. 1998. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4:802-807.
79. Tricoli, J. V., P. H. Gumerlock, J. L. Yao, S. G. Chi, S. A. D'Souza, B. R. Nestok, and R. W. deVere White. 1996. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 15:108-114.
80. Wang, T., B. Y. Li, P. D. Danielson, P. C. Shah, S. Rockwell, R. J. Lechleider, J. Martin, T. Manganaro, and P. K. Donahoe. 1996. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 86:435-444.
81. 1 arrest pathway. Mol. Cell. Biol. 19:5913-5922.
82. West, M. J., M. Stoneley, and A. E. Willis. 1998. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 17:769-780.
83. Woo, M. S.-A., I. Sánchez, and B. D. Dynlacht. 1997. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol. Cell. Biol. 17:3566-3579.
84. 1. Mol. Cell. Biol. 16:3698-3706.
85. Wu, L., C. Timmers, B. Maiti, H. I. Saavedra, L. Sang, G. T. Chong, F. Nuckolls, P. Giangrande, F. A. Wright, S. J. Field, M. E. Greenberg, S. Orkin, J. R. Nevins, M. L. Robinson, and G. Leone. 2001. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414:457-462.
86. Yagi, K., M. Furuhashi, H. Aoki, D. Goto, H. Kuwano, K. Sugamura, K. Miyazono, and M. Kato. 2002. c-myc is a downstream target of the Smad pathway. J. Biol. Chem. 277:854-861.
87. Yano, T., C. A. Sander, H. M. Clark, M. V. Dolezal, E. S. Jaffe, and M. Raffeld. 1993. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 8:2741-2748.
88. Yu, K., L. Toral-Barza, C. Discafani, W. G. Zhang, J. Skotnicki, P. Frost, and J. J. Gibbons. 2001. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8:249-258.
89. Zentella, A., F. M. B. Weis, D. A. Ralph, M. Laiho, and J. Massagué. 1991. Early gene responses to transforming growth factor-β in cells lacking growthsuppressive RB function. Mol. Cell. Biol. 11:4952-4958.
90. Zhu, L., E. Harlow, and B. D. Dynlacht. 1995. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev. 9:1740-1752.
91. Ziv, E., J. Cauley, P. A. Morin, R. Saiz, and W. S. Browner. 2001. Association between the T29→C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The study of osteoporotic fractures. JAMA 285:2859-2863.